Bortezomib
- Generic Name
- Bortezomib
- Brand Names
- Velcade, Bortezomib Accord, Bortezomib Hospira, Bortezomib Fresenius Kabi, Bortezomib Sun
- Drug Type
- Small Molecule
- Chemical Formula
- C19H25BN4O4
- CAS Number
- 179324-69-7
- Unique Ingredient Identifier
- 69G8BD63PP
- Background
Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib.
Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, and solid tumours.
- Indication
Bortezomib is indicated for the treatment of adults with multiple myeloma or mantle cell lymphoma.
- Associated Conditions
- Mantle Cell Lymphoma (MCL), Multiple Myeloma (MM)
- Associated Therapies
- -
A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma
- First Posted Date
- 2007-08-09
- Last Posted Date
- 2015-12-07
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 22
- Registration Number
- NCT00514371
- Locations
- 🇺🇸
Local Institution, Columbia, South Carolina, United States
Velcade (Bortezomib - PS341) in the Treatment of Patients Over 18 Years With Ph+ Leukemia
- Conditions
- First Posted Date
- 2007-08-03
- Last Posted Date
- 2008-11-24
- Lead Sponsor
- University of Bologna
- Target Recruit Count
- 3
- Registration Number
- NCT00511069
- Locations
- 🇮🇹
Policlinico "S.Orsola-Malpighi"-Istituto di Ematologia "L e A Seragnoli", Bologna, Italy
Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2007-08-02
- Last Posted Date
- 2014-05-12
- Lead Sponsor
- Duke University
- Target Recruit Count
- 14
- Registration Number
- NCT00510887
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
Bortezomib and High-dose Melphalan at Myeloma Relapse
- Conditions
- First Posted Date
- 2007-07-27
- Last Posted Date
- 2010-06-22
- Lead Sponsor
- Nordic Myeloma Study Group
- Target Recruit Count
- 50
- Registration Number
- NCT00508209
- Locations
- 🇩🇰
Dept. of Haematology, Århus University Hospital, Århus, Denmark
🇳🇴Department of Hematology, Rikshospitalet, Oslo, Norway
🇩🇰Department of Haematology, Herlev University Hospital, Herlev, Denmark
Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone
- Conditions
- Interventions
- First Posted Date
- 2007-07-26
- Last Posted Date
- 2014-05-01
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 502
- Registration Number
- NCT00507416
- Locations
- 🇺🇸
Hematology Oncology Consultants Inc., Columbus, Ohio, United States
🇺🇸S. Florida Oncology/ Hematology, West Palm Beach, Florida, United States
🇺🇸Hematology-Oncology Clinic, Baton Rouge, Louisiana, United States
Bortezomib (Velcade) Post Allogenic Peripheral Blood Stem Cell Transplantation for Myeloma
- First Posted Date
- 2007-07-20
- Last Posted Date
- 2011-09-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 8
- Registration Number
- NCT00504634
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Bortezomib, Arsenic Trioxide, and Melphalan in Treating Patients Undergoing an Autologous Stem Cell Transplant For Multiple Myeloma
- Conditions
- First Posted Date
- 2007-07-19
- Last Posted Date
- 2016-12-15
- Lead Sponsor
- University of Miami
- Registration Number
- NCT00504101
- Locations
- 🇺🇸
University of Miami Sylvester Comprehensive Cancer Center - Miami, Miami, Florida, United States
Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia
- Conditions
- Interventions
- First Posted Date
- 2007-06-27
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 46
- Registration Number
- NCT00492050
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma
- First Posted Date
- 2007-06-06
- Last Posted Date
- 2013-11-11
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 63
- Registration Number
- NCT00483262
- Locations
- 🇺🇸
Washington University in Saint Louis, St. Louis, Missouri, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸University of Michigan, Ann Arbor, Michigan, United States
Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2007-05-25
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 80
- Registration Number
- NCT00479128
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.